Episodic migraine
Prevention · Established useMigraine prevention, including episodic and chronic populations. TGA approval and PBS eligibility are separate questions.
NICE headache guideline: migraine and cluster headacheFremanezumab (Ajovy)
Fremanezumab (Ajovy) is one option discussed in migraine care. Clea explains where it sits in the treatment landscape without recommending it for an individual person.
Checking review recordSource references are available below.
ROLE BY HEADACHE TYPE
Which patterns is this used for?
Frequency and symptoms can overlap: someone can have chronic migraine and vestibular symptoms, for example. Choose a label to explore usual roles, not to select a treatment for yourself.
General information, not personal medical advice. Some uses are off-label or supported by limited evidence. TGA approval, PBS eligibility and individual suitability differ. Do not start, stop or change treatment without your clinician or pharmacist.
Chronic migraine
Prevention · Established useMigraine prevention, including episodic and chronic populations. TGA approval and PBS eligibility are separate questions.
NICE headache guideline: migraine and cluster headacheMigraine with aura
Prevention · Established usePrevention of migraine burden in people who may experience typical aura; not established as an aura-only treatment.
NICE headache guideline: migraine and cluster headacheMigraine without aura
Prevention · Established useMigraine prevention, including episodic and chronic populations. TGA approval and PBS eligibility are separate questions.
NICE headache guideline: migraine and cluster headacheMenstrual-related migraine
Prevention · Established useMigraine prevention, including episodic and chronic populations. TGA approval and PBS eligibility are separate questions.
NICE headache guideline: migraine and cluster headacheUse labels are an editorial guide to the cited sources, not a clinical recommendation or an independent clinical-review badge. Each profile retains its separate review status.
Where it fits
Migraine-specific preventive therapy.
Administration
Subcutaneous injection.
What we know
Randomised trials support prevention in episodic and chronic migraine populations.
Access
TGA registration and PBS criteria should be checked because subsidy rules can change.
Mechanism, in plain language.
CGRP monoclonal antibodies target CGRP signalling, either the molecule or its receptor depending on the product. They are designed for prevention rather than simply masking pain on one attack day.
Decide what “working” would mean.
For prevention, one attack does not tell you whether the treatment is working. Track headache days, migraine-like days, severity, functional impact and acute-medicine days over the review period your clinician recommends. A useful response can be fewer attacks, less severe attacks, better function or a combination of these.
Questions for the treatment conversation
- What is the goal of using Fremanezumab (Ajovy) in my migraine plan?
- How will we decide whether it is helping enough to continue?
- What side effects or warning signs should I know about?
- Do any of my other medicines, conditions, pregnancy plans or allergies change the discussion?
- What is the current Australian access pathway and likely cost for me?
Give the next review better evidence.
Before and after a treatment change, record migraine-like days, total headache days, acute medicine days, severity and functional impact. If you notice side effects, record what happened and when rather than relying on memory at the next appointment.
Add to My TreatmentsSAFETY
Suitability is individual.
Injection reactions and individual medical circumstances should be discussed with the prescriber.
Clea does not recommend, start, stop or change medicines. Discuss individual treatment decisions with your GP, neurologist, pharmacist or other treating clinician.
DRUGS.COM · EXTERNAL PATIENT REVIEWS
Read the right review category.
Original Drugs.com ratings use a 10-point scale. Read the source condition label and review count before drawing conclusions. “Migraine Prevention” is not a vestibular-only or episodic-only score, and a review category does not establish an approved indication.
Source links only. Clea has not imported ratings or review text. Republishing source scores requires permission; no licensed ratings feed is connected. Drugs.com is US-focused, so medicine names and approved uses may differ from Australia. Reviews are self-selected experiences, not comparative evidence of effectiveness.
CLEA COMMUNITY EXPERIENCE · NOT DRUGS.COM
Compare experiences from the same pattern.
People can report a migraine frequency and a symptom pattern separately, such as chronic plus vestibular. Labels are self-reported, not independently diagnosed or verified. Groups can overlap and cannot establish that one treatment works better than another.
Viewing: All migraine frequencies · All symptom patterns
Loading this group…
Small, self-selected groups are not clinical trials. Scores are perceived experiences and may reflect dose, treatment duration, other conditions and access as well as benefit. No personal identities are published here.
Log in to add your experienceCheck the original source.
Therapeutic Goods AdministrationPharmaceutical Benefits SchemeMigraine & Headache Australia drug directoryKeep your treatment story in one place.
Add treatments you have tried to My Clea, then use your history when preparing for your next appointment.
Open My Clea